Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients

Table 1 Intragroup comparisons between CD117+ and CD117- cases for plasma cells

Group		CD117+ cases	CD117- cases	p value
MGUS	Tot PCs	1.30	1.48	NS
		(0.71–2.40)	(0.36–2.08)	NS
	nPCs	19.17	10.74	NS
		(6.17–82.52)	(5.24–51.64)	NS
	cPCs	80.83	89.26	NS
		(17.48–93.83)	(48.36–94.76)	NS
Therapy	Tot PCs	0.62	0.41	NS
		(0.14–14.40)	(0.12–1.15)	NS
	nPCs	25.19	71.79	NS
		(0.14–70.80)	(1.23–96.12)	NS
	cPCs	74.82	28.21	NS
		(29.20–99.86)	(3.88–98.77)	NS
New	Tot PCs	6.48	13.03	NS
		(0.26–20.19)	(0.44–60.50)	NS
	nPCs	1.68	0.32	0.01
		(0.75–66.12)	(0.05–1.32)	0.01
	cPCs	98.32	99.68	0.01
		(33.88–99.25)	(98.68–99.95)	0.01
Progressive	Tot PCs	2.14	9.03	NS
		(0.75–30.29)	(8.11–23.98)	NS
	nPCs	6.38	0.32	NS
		(0.59–12.88)	(0.25–1.67)	NS
	cPCs	93.62	99.68	NS
		(87.12–99.41)	(98.33–99.75)	NS

Results are expressed as median percentage (range)
Tot PCs total plasma cells, nPCs normal/reactive polyclonal plasma cells (out of total plasma cells), cPCs clonal/aberrant plasma cells (out of total plasma cells), NS not significant
The Mann-Whitney U-test was used for this analysis

ISSN: 1742-4933